Skip to content

Study · Randomized controlled trial · n = 176 · 2017

5 results

Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.

Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, Zheng YX, Liu E, Chen L, Yan JH, Xu W, Mai TT, Gong Y

Clinical endocrinology13 Sept 2017Cited by 111 (Europe PMC)

PMID28834553 (opens in a new tab)DOI10.1111/cen.13454 (opens in a new tab)PepBankPUB-28834553
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, exenatide reduced weight more than metformin.

    In plain wordsIn overweight or obese women with PCOS, exenatide reduced weight more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight reduction
    Study

    n = 176

    Comparator
    Metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 weeksAs given in this study (human).

    Measurements

    Weight reduction
    4.29 kg
    exenatide group
    Weight reduction
    2.28 kg
    metformin group

    Source sentences

    Summary
    After the first 12 weeks of intervention, compared with MET, subjects who received EXE had significantly decreased weight (4.29 ± 1.29 kg vs 2.28 ± 0.55 kg, P < .001)
    2 context sentences
    Summary · context
    This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks.
    Summary · context
    Then all patients were treated with MET alone during the second 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, exenatide reduced total fat percentage more than metformin.

    In plain wordsIn overweight or obese women with PCOS, exenatide reduced body fat percentage more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal fat percentage reduction
    Study

    n = 176

    Comparator
    Metformin
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 weeksAs given in this study (human).

    Measurements

    Total fat percentage reduction
    4.67%
    exenatide group
    Total fat percentage reduction
    1.11%
    metformin group

    Source sentences

    Summary
    and total fat% (4.67 ± 0.09% vs 1.11 ± 0.32%, P < .001),
    2 context sentences
    Summary · context
    This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks.
    Summary · context
    Then all patients were treated with MET alone during the second 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, exenatide improved insulin resistance more than metformin.

    In plain wordsIn overweight or obese women with PCOS, exenatide improved insulin resistance more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHOMA insulin resistance improvement
    Study

    n = 176

    Comparator
    Metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 weeksAs given in this study (human).

    Measurements

    HOMA-IR improvement
    1.3
    exenatide group
    HOMA-IR improvement
    0.59
    metformin group

    Source sentences

    Summary
    improved the homeostasis model of assessment for insulin resistance (1.30 ± 0.58 vs 0.59 ± 0.12, P < .001)
    2 context sentences
    Summary · context
    This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks.
    Summary · context
    Then all patients were treated with MET alone during the second 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, exenatide increased menstrual frequency ratio more than metformin.

    In plain wordsIn overweight or obese women with PCOS, exenatide increased menstrual frequency more than metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMenstrual frequency ratio
    Study

    n = 176

    Comparator
    Metformin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    10 μg twice daily · 12 weeksAs given in this study (human).

    Measurements

    Menstrual frequency ratio increase
    0.62 ratio
    exenatide group
    Menstrual frequency ratio increase
    0.37 ratio
    metformin group

    Source sentences

    Summary
    and increased the menstrual frequency ratio (0.62 ± 0.12 vs 0.37 ± 0.01, P < .001).
    2 context sentences
    Summary · context
    This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks.
    Summary · context
    Then all patients were treated with MET alone during the second 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, initial exenatide increased subsequent natural pregnancy rates versus initial metformin during shared metformin treatment.

    In plain wordsIn women with PCOS, initial exenatide increased later natural pregnancy rates compared with initial metformin while both groups received metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNatural pregnancy rate after initial treatment
    Study

    n = 176

    Comparator
    Metformin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    10 μg twice daily · 12 weeksAs given in this study (human).

    Measurements

    Natural pregnancy rate
    43.6%
    initial exenatide group
    Natural pregnancy rate
    18.7%
    initial metformin group

    Source sentences

    Summary
    During the second 12 weeks, the rate of natural pregnancy of EXE-treated patients was significantly higher than MET-treated patients (43.60% vs 18.70%, P < .05).
    2 context sentences
    Summary · context
    This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks.
    Summary · context
    Then all patients were treated with MET alone during the second 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.